



Proteonomix, Inc. Announces the Publication of Research on Use of Umbilical Cord Blood in Growing Undifferentiated Embryonic Stem Cells

December 18, 2008 10:06 AM ET

Proteonomix, Inc. (PINKSHEETS: PROT) announces the publication in Cloning and Stem Cells Journal Volume 10 No. 4, published on November 20, 2008 by Mary Ann Liebert, Inc., of an article entitled "Cells Derived from Human Umbilical Cord Blood Support the Long-Term Growth of Undifferentiated Human Embryonic Stem Cells."

The publication, authored by Xiangcan Zhan, Ph.D. et al. of The Kennedy Krieger Institute and The Johns Hopkins University, describes the utilization of umbilical cord blood components to act as feeder cells (part of a cell growth medium) for the growth of undifferentiated embryonic stem cells. This breakthrough may provide, for the first time, the ability to grow embryonic stem cells without differentiation on material that is currently being used in human transplants. The technology described in the study was co-invented with the Johns Hopkins University. An undifferentiated cell has the capacity to remain a stem cell until directed to become another type of cell such as a cardiac cell, beta (insulin producing) cell, nerve cell and others.

Human embryonic stem cells are currently cultured with animal feeder cells which can transmit pathogens to the human cells, limiting their ability to be transplanted for medical purposes. Michael Cohen, President of Proteonomix, Inc., is the co-inventor of key components of the technology upon which this publication is based. Proteonomix has begun to commercialize this technology -- initially to academic and corporate research laboratories which are incorporating stem cell therapies in the cure of multiple diseases including, but not limited to, diabetes, cardiac, and neurological diseases.

Michael Cohen commented, "We hope to create a therapeutic laboratory standard by commercializing this technology and licensing it to pharmaceutical companies and hospitals which are developing human embryonic cell therapeutics. We estimate that over 40,000 laboratories in pharmaceutical companies and hospitals could employ this technology."

[About Proteonomix, Inc.](#)

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. It is developing an intellectual property

portfolio in the areas of therapeutics and cosmetics. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter their respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, has developed a line of anti-aging cosmetics. For more information, please visit www.proteonomix.com or www.proteoderm.com and www.pinksheets.com.

"Safe Harbor Statement"

Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto may not occur.

Contact:

Michael Cohen

President

Proteonomix, Inc.

Phone: (973) 544-6116